Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond
Purpose: Radiotherapy is integral in the management of hematological malignancies (HM). Standard radiotherapy dose fractionation regimens range between 20 and 50 Gy in 10–25 fractions over 2–5 weeks. This study presents the outcomes of patients with HM treated with hypofractionation radiotherapy (HF...
保存先:
| 主要な著者: | , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI AG
2024-01-01
|
| シリーズ: | Current Oncology |
| 主題: | |
| オンライン･アクセス: | https://www.mdpi.com/1718-7729/31/1/25 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|